|
⚲
|
| Keyboard |
| Sessa Capital IM LP
✚
|
|
|---|---|
| CRD # | 166403 |
| SEC # | 801-79501 |
| CIK # | 0001595849 |
| AUM | 7,524.2 M (2026-03-31) |
| Employees | 13 (54% Investors, 0% Brokers) |
| Phone | 212-257-4410 |
| Address | 888 Seventh Avenue, 30th Floor New York, NY 10019 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Discovery Communications Inc | 0.9 | ||
| Humana Inc | 0.6 | ||
| PG&E Corp | 0.4 | ||
| Kimberly Clark Corp | 0.4 | ||
| Illumina Inc | 0.4 | ||
| Air Products & Chemicals Inc /DE/ | 0.3 | ||
| Ally Financial Inc | 0.3 | ||
| Sotera Health Co | 0.3 | ||
| Capital One Financial Corp | 0.3 | ||
| Solstice Advanced Materials Inc | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Sessa Capital Special Opportunity Fund III LP | [2022-08-29] | 97.4 M | 1.8 M |
| Filed 2023-06-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sessa Capital Special Opportunity Fund II LP | [2019-03-28] | 867.3 M | 1,907.2 M |
| Filed 2026-01-13 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sessa Capital Special Opportunity Fund I LP | [2016-03-30] | 5.7 M | |
| Filed 2016-02-11 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sessa Capital Master LP | [2013-01-02] | 554.2 M | 5,615.2 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 7.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 7.5 |
| By Discretionary | ||
| Discretionary | 5 | 7.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 7.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 5.6 | |
| United States Persons | 1.9 | |
| Total | 5 | 7.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| John Petry | Executive Officer | 6 | 2 | |
| Sessa Capital GP LLC | Director | 4 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001595849] | |
| 3 | [0001595849] | |
| 4 | [0001595849] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300N2WPE2Q4XDV467 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
SAB Biotherapeutics Inc SABS
Common Stock
|
2025-09-29 | Option exercise | 1,740,000 | $1.75 | 3,045,000 |
|
SAB Biotherapeutics Inc SABS
Series B Convertible Preferred Stock · derivative
|
2025-09-29 | Option exercise | 17,400 | ||
|
SAB Biotherapeutics Inc SABS
Series B Convertible Preferred Stock · derivative
|
2025-07-22 | Grant | 228,500 | ||
|
SAB Biotherapeutics Inc SABS
Warrants (right to buy) · derivative
|
2025-07-22 | Grant | 228,500 | ||
|
SAB Biotherapeutics Inc SABS
Warrants (right to buy) · derivative
|
2025-07-22 | Grant | 114,250 | ||
|
Garrett Motion Inc GTX
Common Stock
|
2024-03-06 | Sell | 10,000,000 | $9.00 | 90,000,000 |
|
SAB Biotherapeutics Inc SABS
Series A-2 Convertible Preferred Stock · derivative
|
2023-11-24 | Option exercise | 28,380 | $1,000.00 | 28,380,000 |
|
SAB Biotherapeutics Inc SABS
Series A-1 Convertible Preferred Stock · derivative
|
2023-11-24 | Option exercise | 31,269 | $1,000.00 | 31,269,000 |
|
SAB Biotherapeutics Inc SABS
Common Stock
|
2023-11-24 | Option exercise | 4,584,571 | ||
|
SAB Biotherapeutics Inc SABS
Series A-1 Convertible Preferred Stock · derivative
|
2023-11-13 | Grant | 13,269 | $1,000.00 | 13,269,000 |
|
SAB Biotherapeutics Inc SABS
Tranche A Warrants · derivative
|
2023-11-13 | Option exercise | 13,269 | ||
|
SAB Biotherapeutics Inc SABS
Tranche B Warrants · derivative
|
2023-11-10 | Grant | 8,846 | ||
|
SAB Biotherapeutics Inc SABS
Tranche C Warrants · derivative
|
2023-11-10 | Grant | 22,115 | ||
|
SAB Biotherapeutics Inc SABS
Tranche A Warrants · derivative
|
2023-11-10 | Grant | 13,269 | ||
|
SAB Biotherapeutics Inc SABS
Series A-1 Convertible Preferred Stock · derivative
|
2023-10-23 | Grant | 16,269 | $1,000.00 | 16,269,000 |
|
SAB Biotherapeutics Inc SABS
Tranche A Warrants · derivative
|
2023-10-23 | Option exercise | 16,269 | ||
|
Garrett Motion Inc GTX
Common Stock
|
2023-06-13 | Option exercise | 1,731,896 | ||
|
Garrett Motion Inc GTX
Series A Preferred Stock · derivative
|
2023-06-06 | Option exercise | 16,592,384 | $0.00 | |
|
Garrett Motion Inc GTX
Common Stock
|
2023-06-06 | Option exercise | 16,592,384 | ||
|
Provention Bio Inc PRVB
Common Stock
|
2023-04-27 | Tender | 15,567,497 | ||
| showing 20 of 30 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Polunin Capital Partners Limited
✚
|
7,959.6 M | |
|
LoanCore Capital Credit Advisor LLC
✚
|
CT | 7,922.4 M |
|
Kensico Capital Management Corp
✚
|
CT | 7,876.6 M |
|
Suvretta Capital Management LLC
✚
|
NY | 7,866.7 M |
|
59 North Capital Management LP
✚
|
TX | 7,503.2 M |
|
Lombard Odier Asset Management USA Corp
✚
|
NY | 7,484.7 M |
|
Morant Wright Management Limited
✚
|
7,430.8 M | |
|
BLS Capital Fondsmaeglerselskab A/S
✚
|
7,218.4 M | |
|
Sachem Head Capital Management LP
✚
|
NY | 7,157.7 M |
|
Daemon Investment and Asset Management LLC
✚
|
FL | 7,098.5 M |